.M., standard error of the mean; * indicates putative nAChR subtype assignment.
INTRODUCTION
Nicotine, the major alkaloid in tobacco, has intrinsic rewarding properties, which maintain chronic tobacco use and dependence. [1] [2] [3] Dopamine (DA) release evoked by nicotine via activation of presynaptic neuronal nicotinic acetylcholine receptors (nAChRs) is thought to mediate nicotine-induced reward, leading to tobacco dependence. [4] [5] [6] [7] [8] [9] [10] Mesocorticolimbic and nigrostriatal DA systems, including the nucleus accumbens, medial prefrontal cortex, and striatum have been implicated in drug-induced reward. The nucleus accumbens shell encodes primary appetitive stimuli associated with unconditioned drug reward, [11] [12] [13] [14] including reward produced by nicotine. 5, [15] [16] [17] The medial prefrontal cortex encodes secondary conditioned stimuli associated with environmental cues paired with drug, leading to reward expectancy. 14, [18] [19] [20] [21] Integration of the motivational information from medial prefrontal cortex occurs at least in part in striatum leading to initiation and execution of movement in reward expectancy and detection of reward. 22 Furthermore, nicotine dose-dependently increases neuronal activity in these brain regions in smokers, as assessed in fMRI and PET studies. 23, 24 
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With varying affinity, nicotine activates all known nAChRs 25 and upon activation, nAChRs modulate the release of various neurotransmitters. [26] [27] [28] [29] Currently available tobacco use cessation agents (ie, nicotine and bupropion) have shown limited efficacy, as relapse rates are reported to be high, [30] [31] [32] [33] indicating a need for the development of alternative, more efficacious smoking cessation pharmacotherapies. The use of nicotine replacement as a cessation therapy is based on activation of nAChRs resulting in DA release within the relevant neural circuitry. Bupropion acts as an inhibitor of the dopamine transporter (DAT), also resulting in increased extracellular DA concentrations. [34] [35] [36] [37] [38] Recently, bupropion has been reported to act as a nAChR antagonist within the same concentration range that it inhibits DAT function. [38] [39] [40] [41] [42] Many studies have shown that nicotine-evoked DA release is completely inhibited by the classical, nonselective, noncompetitive nAChR antagonist, mecamylamine. [43] [44] [45] Mecamylamine has some efficacy as a tobacco use cessation agent, but its therapeutic use is limited by peripherally mediated side effects, eg, constipation and dry mouth. 46, 47 In this respect, one therapeutic strategy is to develop novel subtype-selective nAChR antagonists that inhibit nicotine-evoked DA release in brain. Such antagonists may prove to be efficacious smoking cessation agents with fewer side effects, due to the nAChR subtype-selective action.
nAChRs are composed of 5 subunits and have been shown to have discrete expression patterns. [48] [49] [50] [51] Genes for α2-α7 and β2-β4 subunits have been identified in mammalian brain. [52] [53] [54] [55] Heteromeric nAChRs exist as combinations of α and β subunits, and variations in subunit compositions contribute to differences in nAChR function and pharmacology. [56] [57] [58] [59] [60] In heteromeric nAChRs, β subunits regulate the rate at which agonists and antagonists bind and dissociate from the nAChRs, as well as their pharmacological sensitivity. 61 In addition to heteromeric nAChRs, homomeric nAChRs also are present in the central nervous system, and are believed to consist of 5 α7 subunits. 62 α4β2* and α7* nAChR subtypes are predominant in rodent brain and are probed by highaffinity binding of [ 3 H]nicotine [63] [64] [65] and [ 3 H]methyllycaconitine (MLA) 66 , respectively. nAChRs are located on DA cell bodies and terminals, including the substantia nigra and its terminal fields in striatum. 27 Substantia nigra DA neurons projecting to striatum express mRNA for α3, α4, α5, α6, α7, β2, β3, and β4, [67] [68] [69] [70] suggesting that variations in the combinations of these subunits may be involved in the formation of nAChR subtypes that modulate DA release at striatal presynaptic DA terminals. In this respect, the asterisk behind the nAChR subtype designation indicates the putative subunit composition of the native subtype involved in the response to nicotine. 71 Results showing that both the Conus snail peptide neurotoxin, α-conotoxin MII (α-CtxMII), and the small quaternary ammonium molecules, N-n-pentadecylpyridinium bromide (NPDPB), N-neicosylpyridinium bromide (NEcPB), and bis-picoliniumdodecyl bromide (bPiDDB), only partially inhibit nicotineevoked striatal [ 3 H]DA release indicate the involvement of more than one population of nAChR subtype mediating this response. [72] [73] [74] [75] [76] Initially, the α3β2* nAChR subtype was suggested to mediate nicotine-evoked striatal DA release, based on the observations that neuronal bungarotoxin and α-CtxMII were selective for the α3β2 subtype in recombinant receptor assay systems [77] [78] [79] and that nicotine-evoked DA release was sensitive to inhibition by neuronal bungarotoxin and α-CtxMII. 43, 72, 80 Consistent with the latter results, studies using β2 knockout mice have clearly demonstrated the involvement of β2-containing nAChRs in nicotine-evoked [ 3 H]DA release. 74, [81] [82] [83] However, subsequent studies with α3 knockout and α6 knockout mice showed that [ 125 I]α-CtxMII binding was preserved in α3 knockout mice, but abolished in α6 knockout mice, indicating α-CtxMII also has high affinity for α6-containing nAChRs and that α6-containing nAChRs mediate nicotine-evoked striatal [ 3 H]DA release. [84] [85] [86] α-CtxMII binds to critical residues that are conserved in α3 and α6 subunits, which are closely related. 79, 87 Subsequently, Champtiaux et al 85 suggested that α4β2*, α6β2*, and α4α6β2* subtypes mediate the dopaminergic response to nicotine. α6-and β3-containing nAChRs were also suggested to be implicated in nicotine-evoked DA release by others. 60, 88 α-CtxMII was shown to bind with high affinity to immunopurified α6-and β2-containing nAChRs, which were suggested to consist of α6α2(β3) and α4α6β2(β3) subunit compositions, whereas α4β2 and α4α5β2 subtypes were insensitive to recognition by α-CtxMII. 89, 90 Results from studies using β3-knockout mice also indicate that β3-containting nAChRs mediate α-CtxMII-sensitive nicotineevoked DA release from striatal synaptosomes; however, compensatory increases in α-CtxMII-resistant nicotineevoked DA release were also observed. 90 Additionally, substantia nigra neurons express high levels of both α6 and β3 mRNA, 68, 88, 91, 92 consistent with their involvement in mediating nicotine-evoked DA release.
Recently, a comprehensive molecular genetics study was conducted in which an individual subunit gene (ie, α4, α5, α7, β2, β3, and β4) was deleted. In this study, at least 6 different nAChR subtypes were reported to mediate nicotineevoked DA release in mouse striatal synaptosomes, including 2 classes of nAChRs: α-CtxMII-sensitive nAChRs (ie, α6β2β3*, α4α6β2β3*, and possibly a small amount of α6β2* or α4α6β2* subtypes) and α-CtxMII-resistant nAChRs (ie, α4β2* and α4α5β2* subtypes), whereas deletion of β4 and α7 subunits had no effect. 93 These data show that native subtypes in mouse striatum can consist of at least 5 different subunits. These different subtypes have different E203 pharmacological properties. Thus, the number of relevant nAChR subtypes involved in nicotine-evoked DA release is considerably larger than originally thought. Contemporary molecular genetics and the use of genetically engineered knockout mice, which lack one or more genes encoding specific nAChR subunits, provide a unique opportunity to analyze the pharmacology and functional role of nAChRs in a complex biological system. However, these studies have their associated limitations, in that knockout of a specific receptor subunit during development may lead to compensatory subunit combinations and the ability to provide an adaptive response, which complicates interpretation of the results.
To further complicate the association of a particular response with a specific nAChR subtype, results from recent studies using recombinant receptors have shown that when the ratio of subunit pairs is varied, different subtype classes are formed. Moreover, the function (ie, sensitivity to receptor activation, time to desensitization, and upregulation) of these different subtype classes is also dependent on subunit ratio. 94, 95 Furthermore, exposure to drug (eg, nicotine) also influences nAChR subtype stoichiometry and function in recombinant receptor systems. 95, 96 Evidence has also been obtained that suggests that different DA neurons in the substantia nigra can be categorized based on the expression of the specific subtype composition. 70 Thus, not only is the presence of mRNA for a particular subunit important to neuronal function and to drug response, but the relative ratio of transcribed subunits, the specific expression of nAChR subtypes by different DA neurons, and the pharmacological history of the organism also all potentially play a role in the response to nicotine.
The observation that nAChR subtypes that mediate nicotineevoked DA release are pharmacologically different suggests that subtype-selective antagonists can be developed. As part of our drug development efforts, the nicotine molecule has been modified with the aim of obtaining subtype-selective nAChR antagonists. Simple alkylation of the pyridino Natom converts S(-)-nicotine from a potent, nonselective agonist into a potent, subtype-selective, competitive antagonist. [97] [98] [99] N-n-Decylnicotinium iodide (NDNI; Figure 1a ) potently and competitively inhibits [ 3 H]nicotine binding and nicotine-evoked 86 Rb + efflux from thalamic synaptosomes, but does not inhibit nicotine-evoked [ 3 H]DA release. 45, 100 (also Linda P Dwoskin, unpublished data, 2005) N-nOctylnicotinium iodide (NONI; Figure 1b ) competitively inhibits nicotine-evoked [ 3 H]DA overflow from rat striatal slices (referred to herein as probing α6β2*-containing nAChRs), but does not inhibit [ 3 H]nicotine binding (probing α4β2* nAChRs) to striatal membranes. 45, 100 Furthermore, these analogs do not exhibit affinity for α7* nAChRs, as assessed in [ 3 H]MLA binding assays.
The current research focuses on the development of novel, potent, and selective antagonists at nAChRs mediating nicotine-evoked DA release through structural modification of NONI and NDNI by introduction of unsaturation into the Nn-alkyl chain in these molecules (Figure 1 ). This structural change affords a novel series of unsaturated N-n-alkylnicotinium analogs, which were evaluated in various pharmacological assays. Analog-induced inhibition of nicotine-evoked [ 3 H]DA overflow from superfused striatal slices assessed functional interaction at α6β2*-containing nAChRs. In this assay, DA release was determined under conditions in which the DA transporter (DAT) was blocked by nomifensine.
[ 3 H]Nicotine and [ 3 H]MLA binding assays probed α4β2* and α7* nAChR subtypes, respectively. Analog-induced inhibition of nicotine-evoked 86 Rb + efflux from thalamic synaptosomes assessed whether the analogs acted as agonists or antagonists at α4β2* nAChRs. The ability of these analogs to inhibit [ 3 H]DA uptake into striatal synaptosomes was also determined to assess interaction with DAT. 
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MATERIALS AND METHODS
Chemicals
[ 3 H]Nicotine Binding Assay
The [ 3 H]nicotine binding assay was performed using a previously described method. 75, 100 Briefly, striata from 2 rats were dissected, pooled, and homogenized in 10 vol of ice-cold Krebs-HEPES buffer (in mM: 20 HEPES, 118 NaCl, 4.8 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , pH 7.5). Homogenates were incubated at 37°C for 5 minutes, and then centrifuged (27 000g for 20 minutes at 4°C). Pellets were resuspended in 10 vol of ice-cold MilliQ water and incubated for 5 minutes at 37°C, followed by centrifugation (27 000g for 20 minutes at 4°C). The second and third pellets were resuspended in 10 vol of fresh, ice-cold 10% Krebs-HEPES buffer, incubated for 5 minutes at 37°C, and centrifuged as described above.
Final pellets were stored in 10% Krebs-HEPES buffer at -70°C until assay. During assay, the final pellets were resuspended in 20 vol of ice-cold MilliQ water, which afforded 200 µg protein/100 µL, 102 using BSA as the standard. Binding assays were performed in duplicate in a final volume of 200 µL Krebs-HEPES buffer containing 200 mM Tris (pH 7.5 at 4°C). Assays were initiated by the addition of 100 µL of membrane suspension to assay tubes containing final concentrations of 3 nM [ 3 H]nicotine (50 µL) and 1 of 7 concentrations of analog (0.1 nM to 100 µM; 50 µL). Nonspecific binding was defined in the presence of 10 µM nicotine (50 µL). After a 90-minute incubation at 4°C, reactions were terminated by dilution with 3 mL of ice-cold Krebs-HEPES buffer, followed immediately by filtration through Schleicher and Schuell #32 glass fiber filters (Schleicher and Schuell Inc, Keene, NH) (presoaked in 0.5% polyethylenimine [PEI] , using a Brandel cell harvester [Biomedical Research and Development Laboratories, Inc, Gaithersburg, MD]). Filters were rinsed 3 times with 3 mL of ice-cold Krebs-HEPES buffer and transferred to scintillation vials, 4 mL of scintillation cocktail was added and radioactivity was determined by liquid scintillation spectroscopy (Packard model B1600 TR Scintillation Counter, Packard Instrument Co, Inc, Downer's Grove, IL).
Rb + Efflux Assay
To assess whether the analogs acted as agonists or antagonists at the α4β2* nAChR subtype, the 86 Rb+ efflux assay was performed using a previously published method (Linda P. Dwoskin, unpublished data, 2005). 103 Thalamus was homogenized and centrifuged (1000g, 10 minutes, 4ºC). The supernatant fraction was centrifuged (12 000g, 20 minutes, 4ºC) to obtain the synaptosomal fraction. Synaptosomes were incubated for 30 minutes in 35 µL of buffer (in mM: 140 NaCl, 1.5 KCl, 2.0 CaCl 2 , 1.0 MgSO 4 , and 20 α-D-glucose, pH 7.5) containing 4 µCi of 86 Rb + . 86 Rb + uptake was terminated by filtration of the synaptosomes onto glass fiber filters (6 mm, type A/E; Gelman Instrument Co, Ann Arbor, MI) under gentle vacuum (0.2 atm), followed by 3 washes with buffer (0.5 mL each). Subsequently, each filter with 86 Rb + -loaded synaptosomes was placed on a 13-mm glass fiber filter (type A/E) mounted on a polypropylene platform. Assay buffer (in mM: 125 NaCl, 1.5 KCl, 2.0 CaCl 2 , 1.0 MgSO 4 , 25 HEPES, 20 α-D-glucose, and 1.0 g/L BSA, pH 7.5) was superfused at a rate of 2.5 mL/min. Tetrodotoxin (0.1 mM) and CsCl (5.0 mM) were included in the assay buffer to block voltage-gated Na + and K + channels, respectively, and to reduce the basal rate of 86 Rb + efflux. The ability of analog (1 nM to 100 µM) to inhibit 86 Rb + efflux evoked by 3 µM nicotine was determined. This concentration of nicotine was chosen based on initial nicotine concentration-response analysis as the lowest concentration to evoke maximal 86 Rb + efflux (EC 50 = 0.32 ± 0.08 µM, n = 7). After 8 minutes of superfusion, basal samples (sample/18s) were collected for 2 minutes. Subsequently, synaptosomes were superfused for 3 minutes in the absence or presence of 1 of 6 concentrations of analog. Then, nicotine (3 µM) was added to buffer, and superfusion was continued for an additional 3 minutes, followed by superfusion for 3 minutes with buffer in the absence of either drug. Each aliquot of thalamic synaptosomes was exposed to only one concentration of analog. In each experiment, one aliquot was also exposed to nicotine in the absence of analog, and one aliquot was superfused in the absence of either drug to determine basal 86 Rb + efflux. Radioactivity in superfusate and tissue samples was determined by adding 3.7 mL water to each sample, then measuring Cerenkov radiation using a scintillation counter (model B1600 TR, Packard Instrument Co, Inc, Downer's Grove, IL).
To determine the basal rate of 86 Rb + efflux, an exponential decay curve was used to fit the data points preceding and following superfusion with analog and nicotine (SigmaPlot 2000; SPSS, Inc, Chicago, IL). The drug-evoked increase in 86 Rb + efflux resulting from exposure to the analog, nicotine, or both, was calculated as the fractional increase above baseline. Increases were summed to obtain total 86 Rb + efflux during the period of superfusion with analog and/or nicotine, and normalized to 86 Rb + content in the corresponding synaptosomal sample to reduce variability within and between experiments.
[ 3 H]MLA Binding Assay
The [ 3 H]MLA binding assay was performed using previously published methods. 100 Whole rat brain minus cortex, striatum, and cerebellum, was homogenized in 20 vol of ice-cold hypotonic buffer (in mM: 2 HEPES, 14.4 NaCl, 0.15 KCl, 0.2 CaCl 2 , and 0.1 MgSO 4 , pH 7.5). Homogenates were incubated at 37°C for 10 minutes and centrifuged (29 000g for 17 minutes at 4°C). Pellets were washed 3 times by resuspension in 20 vol of the same buffer, followed by centrifugation using the above parameters. Final pellets were resuspended in the incubation buffer to yield ~150 µg membrane protein/100 µL membrane suspension. Binding assays were performed in duplicate, in a final volume of 250 µL of incubation buffer (in mM: 20 HEPES, 144 NaCl, 1.5 KCl, 2 CaCl 2 , 1 MgSO 4 , and 0.05% BSA, pH 7.5). Binding assays were initiated by the addition of 100 µL of membrane suspension to 150 µL of sample containing 2.5 nM [ 3 H]MLA and 1 of 7 concentrations of analog (1 nM to 1000 µM), and incubated for 2 hours at room temperature. Nonspecific binding was determined in the presence of 1 mM nicotine. Assays were terminated by dilution of samples with 3 mL of ice-cold incubation buffer followed by immediate filtration through Schleicher and Schuell #32 glass fiber filters (presoaked in 0.5% PEI) using the Brandel cell harvester (Biomedical Research and Development Laboratories, Inc.). Filters were rinsed 3 times with 3 mL of ice-cold Krebs-HEPES buffer and transferred to scintillation vials, 4 mL of scintillation cocktail was added and radioactivity was determined by liquid scintillation spectroscopy (model B1600 TR Scintillation Counter, Packard Instrument Co, Inc).
[ 3 H]DA Overflow Assay
Nicotine-evoked [ 3 H]DA overflow from superfused rat striatal slices preloaded with [ 3 H]DA was determined using a previously published method. 45, 75 Briefly, coronal slices of rat striata (500 µm, 6-8 mg) were obtained using Following superfusion for 60 minutes, three 5-minute samples (5 mL/sample) were collected to determine basal [ 3 H]outflow. After collection of the third basal sample, slices from an individual rat were superfused for 60 minutes in the absence (0 nM; control) or presence of analog (10 nM to 100 µM) to determine the intrinsic activity of the analog, ie, ability of the analog to evoke [ 3 H]overflow. Each slice was exposed to only one concentration of analog, which remained in the buffer until the end of the experiment; all concentrations of analog were exposed to striatal slices from each rat (within-subject design). Following 60 minutes of superfusion in the absence or presence of analog, nicotine (10 µM) was added to the superfusion buffer and samples were collected for an additional 60 minutes to determine the ability of the analog to inhibit nicotine-evoked [ 3 H]DA overflow. At least one striatal slice in each experiment was superfused for 60 minutes in the absence of analog, followed by superfusion with 10 µM nicotine to determine nicotineevoked [ 3 H]DA overflow in the absence of analog (nicotine control). Using a repeated-measures design, striata from a single rat were used to determine the concentration effect of analog to release [ 3 H]DA (intrinsic activity) and to determine analog-induced inhibition of nicotine-evoked [ 3 H]DA overflow (antagonist activity).
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To assess analog selectivity with respect to inhibition of the effect of nicotine, the ability of representative analogs, NDNB9e and NONB3t (0.01 µM to 1 µM) to inhibit electrical field stimulation-evoked [ 3 H]DA overflow was determined. Striatal slices were preloaded with [ 3 H]DA, as previously described. Each slice was exposed to only one concentration of analog, and superfusate samples were collected for 60 minutes. Subsequently, electrical field stimulation (1 Hz, 2 ms duration for 2 minutes; total 120 unipolar, rectangular pulses) was applied using a model SD9 stimulator (Grass Instruments, Quincy, MA). At least one control slice in each experiment was field-stimulated in the absence of analog. Superfusion continued for an additional 30 minutes. The number of electrical pulses was chosen to provide [ 3 H]DA overflow similar to that evoked by 10 µM nicotine.
After collection of the superfusate samples, the slices were retrieved from the chambers and solubilized using 1 mL of TS-2 tissue solubilizer. Scintillation cocktail (10 mL) was added to the superfusate samples. The pH and volume of the solubilized tissue samples were adjusted to that of the superfusate samples. Radioactivity in the superfusate and tissue samples was determined by liquid scintillation spectroscopy as previously described.
[ 3 H]DA Uptake Assay
The DAT inhibitor, nomifensine, was included in the superfusion buffer in [ 3 H]DA overflow assays described above, such that potential interaction of the analogs with DAT was not a factor in determining DA release. Potential interaction of the analogs with DAT was determined by evaluating the ability of the analogs to inhibit [ 3 H]DA uptake into striatal synaptosomes using a published method. 104 For each experiment, striata from an individual rat were homogenized in 20 mL of ice-cold 0.32 M sucrose containing 5 mM NaHCO 3 (pH 7.4) with 16 up and down strokes of a Teflon pestle homogenizer (clearance ~0.003 inches). Homogenates were centrifuged (2000g for 10 minutes at 4°C) and the resulting supernatants were again centrifuged (20 000g for 17 minutes at 4°C). Resulting pellets were resuspended in 2.4 mL of icecold assay buffer (in mM: 125 NaCl, 5.0 KCl, 1.5 MgSO 4 , 1.25 CaCl 2 , 1.5 KH 2 PO 4 , 10 α-D-glucose, 25 HEPES, 0.1 EDTA, 0.1 pargyline, and 0.1 ascorbic acid, saturated with 95% O 2 /5% CO 2 , pH 7.4). The final protein concentration was ~400 µg/mL, using BSA as the standard. 101 Assays were performed in duplicate in a total volume of 500 µL. Aliquots of synaptosomal suspension (50 µL containing 20 µg of protein) were added to tubes containing 350 µL of buffer and 50 µL of 1 of 9 concentrations of analog (final concentration, 0.01 nM to 1000 µM) and incubated at 34°C for 5 minutes. Following incubation, 50 µL of 0.1 µM [ 3 H]DA was added to the tubes and incubation continued at 34°C for 10 minutes.
Reactions were terminated by addition of 3 mL of ice-cold assay buffer. Samples were rapidly filtered through Schleicher and Schuell # 32 glass fiber filters (presoaked with 1 mM catechol buffer) using the Brandel cell harvester (Biomedical Research and Development Laboratories). Filters were subsequently washed 3 times with ice-cold assay buffer containing 1 mM catechol, transferred to scintillation vials, 10 mL of scintillation cocktail was added, and radioactivity was determined by liquid scintillation spectroscopy.
Data Analysis
For analog-induced inhibition of 
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The effect of each analog on [ 3 H]DA overflow (intrinsic activity) and its ability to inhibit nicotine-evoked [ 3 H]DA overflow (inhibitory effect) were analyzed by 1-way repeated-measures analysis of variance (ANOVA), where concentration was a within-subjects factor (SPSS version 9.0, Chicago, IL). Where appropriate, Dunnett's t-tests were performed to determine the concentration of analog that either evoked [ 3 H]DA overflow or inhibited [ 3 H]DA overflow, compared with the respective control condition. For comparisons regarding analog intrinsic activity, the control constituted the absence of nicotine or analog (buffer control). For comparisons regarding analoginduced inhibition, the control constituted nicotine in the absence of analog (nicotine control). Additionally, a 2-way repeated-measures ANOVA was performed to analyze the time course of analog inhibition of the nicotine-evoked increase in fractional release. Both analog concentration and time were within-subjects factors. If the 2-way ANOVA revealed a significant concentration × time interaction, then 1-way repeated-measures ANOVAs were performed to determine the specific time points at which a concentration-dependent effect occurred, and Dunnett's t-tests were performed to determine the analog concentrations that were significantly different from the nicotine control (nicotine in the absence of analog). The ability of the analogs to inhibit electrical field stimulation-evoked [ 3 H]DA overflow was analyzed by 1-way repeated-measures ANOVA. Where appropriate, Dunnett's ttest determined significant differences between analog concentration and control (field stimulation-evoked [ 3 H]DA overflow in the absence of analog).
For [ 3 H]DA uptake assays, data were pmol/min/mg expressed as percentage of control ([ 3 H]DA uptake in the absence of analog) and were fit using a 1-site competition model, and nonlinear, nonweighted least-squares regression, such that Y = Bt + (Tp -Bt)/(1 + 10 (log IC50 -X) ), where Y = total specific [ 3 H]DA uptake expressed as a percentage of control, X = logarithm of analog concentration, Bt and Tp were minimum response (held constant at 0%) and maximum response (held constant at 100%), respectively. The log IC 50 With respect to the 86 Rb + efflux assay, both analog-induced intrinsic activity and the ability of analog to inhibit nicotineevoked 86 Rb + efflux were analyzed using 1-way repeatedmeasures ANOVA. Basal rate of 86 Rb + efflux was determined using an exponential decay curve to fit the data points preceding and following superfusion with analog and nicotine (SigmaPlot 2000; SPSS, Inc, Chicago, IL).
RESULTS
Inhibition of [ 3 H]Nicotine Binding
Analogs were evaluated for inhibition of [ 3 H]nicotine binding to rat striatal membranes to determine their affinity at α4β2 * nAChRs (Figure 2 ). In the NONI series, introduction of an unsaturated bond into the n-octyl chain resulted in a 4-fold to 250-fold increase in the affinity (K i = 0.08 -4.49 µM) for the [ 3 H]nicotine binding site, when compared with the parent compound NONI (K i = 19.7 µM). Furthermore, all of the compounds completely inhibited [ 3 H]nicotine binding, with the exception of NONB3t and NDNB4c, both of which displayed 87% inhibition at the highest concentration (100 µM) tested (Figure 2 ). NONB3c displayed the highest affinity (K i = 0.08 µM) of the analogs in the NONI series. In the NDNI series, with the exception of NDNB9e (K i = 0.05 µM), affinity of the analogs for the [ 3 H]nicotine binding site decreased 4-fold to 80-fold compared with the parent compound NDNI (K i = 0.09 µM). These results demonstrate that introduction of unsaturation into the n-alkyl chain of NONI enhanced the affinity for α4β2* nAChR subtypes; in contrast, introduction of unsaturation into the n-alkyl chain of NDNI diminished affinity for α4β2* nAChRs, with the exception of NDNB9e (terminal C 9 - E208 double-bond), which showed a slight but significant increase in affinity at this site.
Inhibition of Nicotine-Evoked 86 Rb + Efflux
Since inhibition of [ 3 H]nicotine binding does not indicate if the analogs act as agonists or antagonists at α4β2* nAChRs, representative analogs from the NONI (ie, NONB7e and NONB3y) and NDNI (ie, NDNB4t and NDNB3y) series were investigated for their ability to induce 86 Rb + efflux (intrinsic agonist activity) and/or to inhibit nicotine (3 µM)-evoked 86 Rb + efflux from 86 Rb + preloaded rat thalamic synaptosomes. None of the analogs evoked 86 Rb + efflux above basal outflow (data not shown). In the NONI analog series, NONB7e and NONB3y inhibited nicotine-evoked 86 Rb + efflux (IC 50 values 2.42 and 1.66 µM, respectively), and thus, these unsaturated analogs were 3-fold to 4-fold more potent inhibitors compared with NONI (IC 50 = 6.09 µM) (Figure 3) . Similarly, in the NDNI series, NDNB4t and NDNB3y inhibited nicotine-evoked 86 Rb + efflux (IC 50 = 1.21 and 0.69 µM, respectively) when compared with NDNI (IC 50 = 13.5 nM). Thus, these data demonstrate that these analogs act as antagonists at α4β2* nAChRs.
Inhibition of [ 3 H]MLA Binding
The ability of the analogs to inhibit [ 3 H]MLA binding to rat whole brain membranes is illustrated in Figure 4 . Only relatively high concentrations of each of the analogs in both the NONI and NDNI series inhibited [ 3 H]MLA binding. NDNB9e exhibited a K i value of 16.5 µM; however, the remaining unsaturated analogs and the parent compounds exhibited K i values greater than 100 µM, demonstrating low affinity for α7* nAChRs. Thus, introduction of unsaturation into the nalkyl chain of NONI and NDNI did not improve affinity for α7* nAChRs over the parent compounds.
[ 3 H]DA Overflow: Intrinsic Activity
The ability of analogs to evoke [ 3 H]DA overflow from superfused rat striatal slices preloaded with [ 3 H]DA was determined (Table 1) . One-way repeated-measures ANOVA revealed a significant effect of concentration for each analog (NONB3c, F 5,20 = 36.375, P < .001; NONB3t, F 5,25 = 37.719, P < .001; NONB7e, F 5,23 = 4344.3, P < .001; NONB3y, F 5,18 = 65.877, P < .001; NDNB4c, F 5,34 = 112.308, P < .001; NDNB4t, F 5,29 = 71.529, P < .001; NDNB9e, F 5,25 = 29.881, P < .001; NDNB3y, F 5,9 = 125.939, P < .001). Post hoc analysis revealed that the highest concentration of each analog (100 µM) evoked [ 3 H]DA overflow. In addition, each of the NDNI series of analogs evoked [ 3 H]DA overflow at 10 µM, and the parent NDNI also exhibited intrinsic activity at 1.0 µM. Unsaturated N-n-alkylnicotinium analogs of NONI and NDNI inhibit nicotine-evoked 86 Rb +_ efflux from superfused rat thalamic synaptosomes. Data are presented as mean ± SEM percentage of 86 Rb + tissue content expressed as % of control for n = 4-7 rats/analog. Control is 86 Rb + -efflux in response to 3 µM nicotine (0.7% ± 0.06% 86 Rb + tissue content) in the absence of analog. Curves were generated using nonlinear regression. Abbreviations for the analogs are defined in Figure 1 
Inhibition of Nicotine-Evoked [ 3 H]DA Overflow
Analogs were evaluated for their ability to inhibit nicotine (10 µM)-evoked [ 3 H]DA overflow from rat striatal slices, and the results are illustrated in Figure 5 . One-way repeatedmeasures ANOVA revealed significant concentrationdependent inhibition for each analog (NONB3c, F 4,15 = 14.219, P < .001; NONB3t, F 4,17 = 19.113, P < .001; NONB7e, F 4,17 = 9.432, P < .001; NONB3y, F 4,12 = 9.552, P < .001; NDNB4c, F 3,16 = 4.40, P = .015; NDNB4t, F 3,13 = 21.861, P < .001; NDNB9e, F 3,17 = 13.533, P = .001), with the exception of NDNB3y (F 3,5 = 0.864, P = .509). Each of the analogs within the NONI series inhibited nicotine-evoked [ 3 H]DA overflow (IC 50 = 80 to 250 nM), exhibiting a 3-fold to 8-fold greater potency compared with NONI (IC 50 = 620 nM). NONI and each of the double-bond analogs (NONB3c, NONB3t, NONB7e) exhibited a maximal effect (Imax) of 80% to 89% inhibition compared with control (nicotineevoked [ 3 H]DA overflow in the absence of analog). In contrast, the Imax for the triple-bond analog, NONB3y, was only 50%. Importantly, the N-n-decyl parent compound, NDNI, did not inhibit nicotine-evoked [ 3 H]DA overflow (data not shown). Although NDNI had no inhibitory effect, NDNB4t and NDNB9e did inhibit nicotine-evoked [ 3 H]DA overflow (IC 50 = 20 to 140 nM, Imax = 84% to 88%). Furthermore, NDNB4c (IC 50 = 80 nM) exhibited an Imax = 50%, whereas NDNB3y, similar to NDNI, showed no inhibition. The rank order of potency for the analogs to inhibit nicotine-evoked [ 3 H]DA overflow was NDNB9e > NONB3c = NONB3t = NDNB4c > NONB3y = NDNB4t = NONB7e > NONI >> Table 1 . High concentrations of unsaturated N-n-alkylnicotinium analogs of NONI and NDNI evoke [ 3 H]DA overflow from superfused rat striatal slices. Slices were preloaded with [ 3 H]DA and superfused for 60 minutes with buffer containing nomifensine (10 µM) and pargyline (10 µM) to inhibit the reuptake of released [ 3 H]DA and to prevent metabolism of [ 3 H]DA, respectively. Subsequently, slices were superfused for 60 minutes either in the absence (control) or presence of analog, which was added to the superfusion buffer. Data represent [ 3 H]DA overflow during the latter 60-minute period of superfusion. Each slice was exposed to only one concentration of analog. Abbreviations for the analogs are defined in Figure 1 . . Data are expressed as % of control for n = 5-7 rats/analog. Curves were generated using nonlinear regression. Data for NONI and NDNI are taken from Wilkins et al. 45 Abbreviations for the analogs are defined in Figure 1 . Open symbols represent NONI series analogs and closed symbols represent NDNI series analogs. E210 NDNB3y = NDNI. NDNB9e was the most potent analog (IC 50 = 20 nM) to inhibit nicotine-evoked [ 3 H]DA overflow, indicating high affinity for α6β2*-containing nAChRs.
Analog
Time courses for inhibition of the effect of nicotine exhibited by a representative analog from the NONI series, ie, NONB3c, and a representative analog in the NDNI series, ie, NDNB9e, are illustrated in Figure 6 . Repeated-measures 2-way ANOVA revealed a significant concentration × time interaction for NONB3c (F 44,164 = 1.673, P = .011) and for NDNB9e (F 33,185 = 4.713, P < .001). Nicotine-evoked fractional DA release peaked 10 to 15 minutes after addition of the nicotine to the buffer, and then gradually decreased toward basal levels, despite the continual presence of nicotine in the superfusion buffer throughout the remainder of the experiment. The time course also illustrates the concentration-dependent inhibition exhibited by both NONB3c and NDNB9e. Post hoc analysis revealed that 0.1 µM and 1 µM NONB3c inhibited nicotine-evoked fractional DA release from 25 to 60 minutes, and that 10 µM NONB3c inhibited the response to nicotine at 5 minutes and from 20 to 60 minutes. NDNB9e (0.1 µM) inhibited nicotine-evoked fractional DA release from 5 to 60 minutes; NDNB9e (1.0 µM) inhibited the response to nicotine from 5 to 50 minutes.
Unsaturated N-n-Alkylnicotinium Analogs Do Not Inhibit Field Stimulation-Evoked [ 3 H]DA Overflow
To assess the selectivity of analog-induced inhibition of the effect of nicotine, one analog from each of the NONI and NDNI series (ie, NONB3t and NDNB9e, respectively) was evaluated for its ability to inhibit electrical field stimulationevoked [ 3 H]DA overflow, and the data are provided in Table  2 . Striatal slices were superfused for 60 minutes in the absence (control) or presence of analog and then field stimulation was applied. One-way repeated measures ANOVA revealed that NONB3t inhibited electrically evoked [ 3 H]DA overflow (F 4,14 = 16.376, P < .001); however, post hoc analysis revealed that significant inhibition occurred only at the highest concentration (10 µM), which is 3 orders of magnitude higher than that which inhibits nicotine-evoked [ 3 H]DA overflow (see Table 3 ). Although NDNB9e tended to decease [ 3 H]DA overflow evoked by field stimulation, the decrease did not reach significance (F 3,15 = 1.924, P = .169). Thus, the results indicate that these analogs selectively inhibit nicotineevoked [ 3 H]DA overflow.
Inhibition of [ 3 H]DA Uptake
The ability of all of the NONI and NDNI analogs to inhibit [ 3 H]DA uptake into striatal synaptosomes was determined, and the data are illustrated in Figure 7 . Analogs in both the NONI and NDNI series displayed low affinity for DAT (K i = 16 to 100 µM and 2.5 to 5.3 µM, respectively), similar to NONI and NDNI (K i = 16 and 0.99 µM, respectively). Generally, the NDNI series of unsaturated analogs appeared to be more potent at inhibiting DAT function than the NONI series of unsaturated analogs. Thus, introduction of unsaturation into the n-alkyl chain of NONI and NDNI does not lead to enhancement of affinity for DAT.
DISCUSSION
The current study demonstrates that introduction of unsaturation into the n-alkyl chain of the NONI molecule enhances 
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affinity at both α4β2* (probed by [ 3 H]nicotine binding) and α6β2*-containing nAChRs (probed by nicotine-evoked [ 3 H]DA release); whereas introduction of unsaturation into the n-alkyl chain of the NDNI molecule produces mixed effects, reducing affinity at α4β2* (with the exception of NDNB9e, which was equipotent with NDNI), and uncovering an antagonist effect at α6β2*-containing nAChRs with analogs NDNB4c, NDNB4t and NDNB9e. The current study shows that in the NONI series, introduction of a C 3 -cis-(NONB3c), a C 3 -trans-(NONB3t), or a terminal C 7 -double-bond (NONB7e), or a C 3 -triple-bond (NONB3y) resulted in a 4-fold to 250-fold increase in affinity for the [ 3 H]nicotine binding site (K i = 0.08, 4.49, 0.46, and 0.20 µM, respectively) compared with the parent compound NONI (K i = 19.7 µM). Interestingly, there is some evidence for a geometric structural effect, since the C 3 -cis-analog (NONB3c) is 60-fold more potent at the α4β2* nAChRs than the C 3 -trans-analog (NONB3t). Thus, NONB3c, the most potent analog in this series, is in excess of 2 orders of magnitude greater in potency at the α4β2* nAChR than 50 = 0.62 µM). Interestingly, there was no evidence of a geometrical isomeric effect at α6β2*-containing nAChRs, since the C 3 -cis-and C 3 -transanalogs had similar potency in inhibiting nicotine-evoked [ 3 H]DA release. Thus, introduction of unsaturation into the C 3 position of the n-alkyl chain of NONI did not alter affinity greatly. However, more importantly, introduction of a C 3 cis-or trans-double-bond (eg, NONB3c and NONB3t, respectively) afforded a maximal inhibition (Imax) of ~90%, whereas introduction of a C 3 triple bond (NONB3y) significantly reduced maximal inhibition (Imax = 50%). The current results suggest that NONB3y selectively inhibits only one subtype of nAChR mediating nicotine-evoked DA release, whereas NONB3c and NONB3t interact with more than one nAChR subtype involved in this response. The subtype-selective interaction must be related to a unique geometry of the C 3 triple bond analog (NONB3y), which appears to have the ability to interact with only one nAChR subtype involved in this response to nicotine. This lack of complete inhibition exhibited by some of these NONI analogs is similar to that exhibited by α-CtxMII, and the implication is that more than one nAChR subtype mediates nicotine-evoked DA release (see Introduction). However, several different subtypes may be mediating the effect of nicotine to release DA in striatum. 93 It is important to note that the previous DA release study was conducted using mouse striatal synaptosomes, whereas rat striatal slices were used in the current study. In the more intact preparations, at high micromolar concentrations of nicotine, α7* nAChRs evoke [ 3 H]DA release via an indirect mechanism, ie, by releasing glutamate, which in turn stimulates the release of DA. 106, 107 However, in the current study, unsaturated NONI analogs exhibit no interaction with [ 3 H]MLA binding sites, suggesting that this indirect mechanism may not be involved. Thus, introduction of unsaturation into the n-alkyl chain of NONI afforded compounds with slightly greater potency than NONI in inhibiting nicotine-evoked DA release; however, more importantly, the introduction of a triple bond at C 3 afforded an analog (ie, NONB3y) that may interact with one of a subset of nAChRs mediating nicotine-evoked DA release.
NONI and its unsaturated analogs evoke DA release at a concentration of 100 µM, which is 2 to 3 orders of magnitude higher than the concentration required to inhibit nicotineevoked DA release, indicating that these compounds are inhibitors and do not appear to act as partial agonists. Furthermore, the representative unsaturated NONI analog, NONB3t, did not inhibit electrical field stimulation-evoked DA release at concentrations less than 10 µM. Thus, NONB3t did not inhibit depolarization-induced release evoked by electrical field stimulation at concentrations that are 2 orders of magnitude lower than that which inhibits the effect of nicotine to evoke DA release. These results provide supporting evidence that the above unsaturated NONI analogs act as selective antagonists at nAChRs mediating nicotine-evoked DA release.
The DA release assay was conducted with nomifensine and pargyline included in the superfusion buffer to inhibit the reuptake and prevent the metabolism of released DA, respectively. Since DA collected in superfusate is a reflection of extracellular DA concentrations, it was considered necessary to evaluate interaction of the NONI analogs with DAT, a protein that has profound influence on extracellular DA concentrations. The current work demonstrates that none of the analogs in the NONI series had significant affinity for DAT. Thus, the results suggest that the NONI analogs inhibit 
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nAChRs modulating nicotine-evoked DA release, and do not alter extracellular DA concentrations via an interaction with DAT. Table 3 also provides the results with the unsaturated analogs in the NONI series from assays probing α4β2* and α7* nAChRs. None of the unsaturated NONI analogs had appreciable affinity for α7* nAChRs. NONB3c was the most potent NONI analog to inhibit [ 3 H]nicotine binding and was 2 orders of magnitude more potent than NONI. However, it is important to note that NONB3c is equipotent at both α4β2* at α6β2*-containing nAChRs, indicating that it is not a nAChR subtype-selective agent. Similarly, NONB7e and NONB3y were 1 to 2 orders of magnitude more potent than NONI at α4β2* nAChRs, but were equipotent at α4β2* at α6β2*-containing nAChRs. NONB3t was 20-fold more potent than NONI at α4β2*, and was 50-fold more potent at α6-containing nAChRs compared with α4β2* nAChRs. Thus, introducing unsaturation into the n-alkyl chain of the NONI molecule afforded compounds that were more potent at α6β2*-containing nAChRs, but demonstrated less subtype selectivity.
Introduction of unsaturation into the n-alkyl chain of NDNI provided some unexpected findings. NDNI is a selective Nn-alkylnicotinium antagonist at α4β2* . Additionally, of all the analogs in both series, NDNI exhibited the highest affinity for DAT (K i = 1.0 µM); however, similar to the NONI series compounds, NDNI has little to no affinity for α7* nAChRs. None of the analogs in the unsaturated NDNI series had significant affinity for α7* nAChRs. In the unsaturated NDNI series, introduction of a C 4 -cis-(NDNB4c) or C 4 -trans-double-bond (NDNB4t), or a C 3 -triple bond (NDNB3y) resulted in a 4-fold to 80-fold decrease in affinity for the [ 3 H]nicotine binding site (K i = 7.47, 0.32, and 0.57 µM, respectively) compared with NDNI (K i = 0.09 µM). On the other hand, introduction of a terminal C 9 double-bond (NDNB9e) did not significantly alter affinity (K i = 0.05 µM) at the α4β2* nAChR site, but provided the most potent α4β2* ligand in this series. Interestingly, the C 4 -trans-analog (NDNB4t) was 20-fold more potent than the C 4 -cis-analog (NDNB4c) in inhibiting [ 3 H]nicotine binding, demonstrating a significant geometrical isomeric effect of the C 4 -double bond isomers. Representative analogs from the NDNI series (NDNB3y and NDNB4t) inhibited nicotine-evoked 86 Rb + efflux, indicating their action as α4β2* nAChRs antagonists.
With respect to α6β2*-containing nAChRs, NDNI exhibited intrinsic activity at 1.0 µM, whereas a 1 order of magnitude higher concentration was required to observe intrinsic acitivty with the unsaturated analogs, suggesting that the unsaturated analogs may afford great selectivity towards inhibition. The unsaturated analogs NDNB4t and NDNB9e, which contain double bonds at the C 4 and C 9 positions of the n-decanyl moiety, respectively, potently inhibited nicotine-evoked [ 3 H]DA overflow (IC 50 = 0.14 and 0.02 µM, respectively). This observation was surprising, and demonstrates that introduction of unsaturation into the n-alkyl chain of NDNI converts it from an inactive compound into the most potent α6β2*-nAChR antagonist in the series of unsaturated NDNI analogs. In contrast, introduction of a C 3 triple bond (NDNB3y) into the n-decanyl moiety of NDNI resulted in an inactive analog in this assay, maintaining a profile similar to NDNI. The C 4 -cis-and C 4 -trans-analogs of NDNI had similar potency in inhibiting nicotine-evoked [ 3 H]DA release, indicating a lack of a geometric effect at the α6β2*-containing nAChR. The finding of a C 4 geometrical isomeric effect in the [ 3 H]nicotine binding, but not in the nicotine-evoked [ 3 H]DA release assay, provides additional support that these 2 assays probe different nAChR subtypes (ie, α4β2* and α6β2* subtypes, respectively). Interestingly, the above analogs had significantly different Imax values in the nicotine-evoked [ 3 H]DA release assay, with the C 4 trans-analog (NDNB4t) affording nearly complete inhibition (Imax = 80% to 90%) and the C 4 -cis-analog (NDNB4c) exhibiting an Imax of only 50%. Thus, the cis geometrical isomer appears to selectively inhibit only one nAChR subtype involved in this response, whereas the trans-geometrical isomer inhibits both or all subtypes involved. The current results also suggest that the trans-isomer inhibits the cis-selective subtype with the same affinity as it inhibits the other subtype(s). These structure-activity relationships (SAR) are complex and could be due to the high degree of conformational flexibility inherent in these series of compounds. Future efforts will focus on conformational preferences within these series of molecules using sophisticated molecular modeling approaches.
With respect to the selectivity of the inhibition of nicotineevoked [ 3 H]DA release, the representative analog, NDNB9e, completely inhibited the effect of nicotine at 100 nM (IC 50 = 20 nM). Importantly, NDNB9e did not significantly inhibit field stimulation-evoked [ 3 H]DA release at NDNB9e concentrations, which completely inhibited nicotine-evoked [ 3 H]DA release (Table 2 and Figure 5 ). NDNB9e produced 30% inhibition of field stimulation-evoked release, however this inhibition did not reach significance. Thus, in the unsaturated NDNI series, NDNB9e is the most potent analog (IC 50 = 20 nM) and appears to selectivity inhibit the effect of nicotine to evoke DA release assay; however, this compound is not nAChR subtype-selective, also being the most potent analog (K i = 50 nM) in the [ 3 H]nicotine binding assay. Thus, NDNB9e has similar affinity at α6β2*-containing and α4β2* nAChRs subtypes.
Thus, in summary, introduction of n-alkyl chain unsaturation into the NONI molecule enhanced affinity at both α4β2* and α6β2*-containing nAChRs; however, a general reduction of affinity at α4β2* and an uncovering of antagonist effects at α6β2*-containing nAChRs resulted from similar modification of NDNI. Evaluation of the present structure-activity relationships reveals that the N-n-alkyl chain in the NONI and NDNI series of compounds is not producing nAChR inhibition through a physicochemical mechanism, ie, related to lipophilicity and log P (partitioning). Thus, each of the nAChR subtypes appears to be able to accommodate the N-n-alkyl substituent in a unique conformational geometry. Therefore, the conformation of the n-alkyl chain is an important criterion that contributes to the pharmacological activity, ie, both potency and selectivity at each of the nAChR subtypes. Thus, the availability of analogs that reflect different conformations and geometries of the N-n-alkyl substituent may afford opportunities for the development of more potent and more selective antagonists within these series of compounds, and the introduction of unsaturation into the N-n-alkyl chain is one way of providing a series of unique geometries of NONI and NDNI. These SARs are complex due to the many possible conformations that these flexible unsaturated molecules can adopt. Additional complexity arises with respect to the many potential nAChR subtypes that may be involved in nicotine-evoked DA release. Thus, the specific nAChR subtype(s) mediating nicotine-evoked DA release in the current study is not known; as a result, this complicates the drug discovery process with respect to the development of subtype-selective nAChR antagonists. To obtain a better understanding of these complex interactions, state-of-the-art molecular modeling approaches will be employed in future studies.
